Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-03-08
What Is Substance P? Benefits, Research & Safety
A key neuropeptide involved in pain transmission, inflammation, and mood regulation, and the target of the first neuropeptide receptor antagonist drug.
Also known as:
SP
Neurokinin A precursor
Tachykinin
Educational Content Only: This page provides research-based information for educational purposes. Substance P is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Neuropeptides
Half-Life
Very short (minutes) due to rapid enzymatic degradation by neutral endopeptidase
UK Status
Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.
EU Status
Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.
Overview
Substance P is an 11-amino acid neuropeptide belonging to the tachykinin peptide family. It is one of the most extensively studied neuropeptides, with critical roles in pain transmission, neurogenic inflammation, mood regulation, and gut function.
Substance P is widely distributed throughout the nervous system, particularly in sensory neurons (C-fibres and Aδ-fibres), the spinal cord, and brain regions involved in pain processing, emotional regulation, and the vomiting reflex. It acts primarily through the neurokinin-1 receptor (NK1R).
In pain processing, Substance P is released from primary afferent nerve terminals in the spinal cord dorsal horn, where it amplifies pain signals and contributes to central sensitisation. In peripheral tissues, it triggers neurogenic inflammation—vasodilation, plasma extravasation, and immune cell recruitment.
The development of NK1R antagonists represented a major advance in understanding Substance P's functions. While initial trials for pain relief were disappointing, the NK1R antagonist aprepitant proved highly effective as an anti-emetic (preventing chemotherapy-induced nausea and vomiting), leading to its approval as Emend.
Substance P and NK1R have also been implicated in mood disorders, with research suggesting that NK1R antagonists may have antidepressant and anxiolytic properties, though clinical trial results have been mixed.
Discovery & History
Substance P was one of the first neuropeptides discovered. Ulf von Euler and John Gaddum identified it in 1931 in equine brain and intestinal extracts as a substance that caused smooth muscle contraction and vasodilation. They named it "Substance P" with "P" standing for "preparation" or "powder."
The complete amino acid sequence was determined by Susan Leeman and colleagues in 1971, revealing it to be an 11-amino acid peptide (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2).
In the 1970s-1980s, immunohistochemical studies revealed Substance P's widespread distribution in the nervous system. Its role in pain transmission was established through studies showing its presence in sensory neurons and spinal cord.
The cloning of the NK1 receptor in the early 1990s enabled development of selective antagonists. Merck developed aprepitant (MK-869), initially as an analgesic/antidepressant. While analgesic trials were unsuccessful, its anti-emetic efficacy was remarkable, leading to FDA approval as Emend in 2003.
Research continues into NK1R antagonists for depression, anxiety, and other conditions.
Mechanism of Action
Substance P signals primarily through the NK1 receptor:
**NK1 Receptor Activation**
Primary signaling pathway:
- Binds NK1R (a G-protein coupled receptor) with highest affinity
- Activates Gq/11 signaling cascade
- Increases intracellular calcium via IP3
- Activates protein kinase C and downstream effectors
**Pain Transmission**
Role in nociceptive processing:
- Released from C-fibre terminals in spinal cord dorsal horn
- Enhances NMDA receptor activation (central sensitisation)
- Amplifies pain signals through "wind-up" phenomenon
- Contributes to chronic pain states through neuroplastic changes
**Neurogenic Inflammation**
Peripheral inflammatory effects:
- Vasodilation via endothelial NK1R activation
- Plasma extravasation (increased vascular permeability)
- Mast cell degranulation and histamine release
- Immune cell recruitment and activation
- Contributes to conditions like migraine, arthritis, and IBD
**Emetic Pathway**
Role in nausea and vomiting:
- Acts on NK1R in the nucleus tractus solitarius and area postrema
- Key mediator of chemotherapy-induced delayed emesis
- Target for anti-emetic drugs (aprepitant, fosaprepitant)
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Understanding pain transmission mechanisms
- 2NK1R antagonists approved as anti-emetics (aprepitant/Emend)
- 3Potential target for chronic pain therapeutics
- 4Research into antidepressant effects of NK1R blockade
- 5Biomarker for neuroinflammatory conditions
- 6Role in wound healing and tissue repair
- 7Understanding neurogenic inflammation
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Substance P itself is not administered therapeutically |
| Frequency | N/A |
| Duration | N/A |
| Notes | Substance P is an endogenous neuropeptide. Clinical interest focuses on NK1R antagonists that block Substance P's effects. Aprepitant (Emend) is the primary approved NK1R antagonist, used for prevention of chemotherapy-induced nausea. |
Administration Routes
Routes studied in research settings (educational only):
- Not administered therapeutically (endogenous neuropeptide)
- Used in research for pain/inflammation studies
| Half-Life | Stability |
|---|---|
| Very short (minutes) due to rapid enzymatic degradation by neutral endopeptidase | Rapidly degraded in vivo; research preparations require protease inhibitors |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Not administered therapeutically
Rare Risks & Concerns
- Elevated Substance P levels associated with chronic pain and inflammation
- Excessive neurogenic inflammation
- Contribution to inflammatory disease pathology
Contraindications
- Not a therapeutic agent
UK & EU Regulatory Context
🇬🇧 United Kingdom
Substance P is an endogenous peptide used as a research tool. NK1R antagonists (aprepitant) are licensed medications.
🇪🇺 European Union
Same—Substance P is a research tool; NK1R antagonists are approved anti-emetics.
Substance P itself is not a therapeutic but is crucial for understanding pain and inflammation. NK1R antagonists represent an important therapeutic class. Research continues into broader applications of NK1R blockade.
Clinical Studies Summary
NK1R Antagonists for Chemotherapy-Induced Nausea
Pivotal trials demonstrating aprepitant's efficacy in preventing chemotherapy-induced nausea and vomiting, leading to FDA approval.
New England Journal of Medicine. 2003View on PubMed
Substance P and Depression
Studies investigating elevated Substance P levels in depression and the potential antidepressant effects of NK1R antagonists.
Psychiatry and neuroscience journalsView on PubMed
Looking for Substance P?
Source research-grade Substance P from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Peptides
DSIP
A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.
Learn moreVasopressin
A hormone essential for water balance and blood pressure regulation, also involved in social behavior and stress responses.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn moreBeta-Endorphin
The body's natural opioid peptide involved in pain modulation, stress response, and reward, mediating the 'runner's high' and other euphoric states.
Learn more